1. Articles in category: News

    1-24 of 244 1 2 3 4 ... 9 10 11 »
    1. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    2. Epigenetic analysis: Giving the right name to a tumor

      Epigenetic analysis: Giving the right name to a tumor

      ( Heidelberg University Hospital and Medical Faculty ) Scientists from the 'Hopp Children's Cancer Center at the NCT Heidelberg' (KiTZ) and the Neuropathology Department at Heidelberg University Hospital have substantially enhanced the classification of tumors of the central nervous system (CNS) / Physicians will now be able to categorize CNS tumors more precisely into specific risk groups and make therapy decisions on this basis / The method was developed in close collaboration with the German Cancer Consortium (DKTK) / Publication in Nature.

      Read Full Article
    3. Study identifies two new biomarkers for common form of childhood cancer

      Study identifies two new biomarkers for common form of childhood cancer

      Two new biomarkers for a type of cancer in children called neuroblastoma have been identified in a study published in the journal Cancer Cell. The findings are expected to have immediate significance for disease prognosis, and eventually also for treatment. "There is a need for new methods of ...

      Read Full Article
    4. Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Radiographics. 2018 Mar-Apr;38(2):566-580

      Authors: Swift CC, Eklund MJ, Kraveka JM, Alazraki AL

      Abstract Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the most common extracranial solid tumor of childhood and accounts for up to 15% of all pediatric cancer fatalities.

      Read Full Article
      Mentions: Treatment
    5. Combination therapy in neuroblastoma: It`s all about the mix

      The combination of two cell division inhibitors causes malignant nervous system tumors to die off, as scientists from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have shown in experimental studies.The combination strategy could be the key to new targeted therapies against this aggressive type of tumor. The Hopp Children’s Cancer Center at […]

      The post Combination therapy in neuroblastoma: It`s all about the mix appeared first on Healthcanal.com.

      Read Full Article
      Mentions: ALK
    6. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Exp Cell Res. 2018 Feb 27;:

      Authors: Xu DQ, Toyoda H, Yuan XJ, Qi L, Chelakkot VS, Morimoto M, Hanaki R, Kihira K, Hori H, Komada Y, Hirayama M

      Abstract Neuroblastoma (NB) is one of the most common solid tumors in children. High-risk NB remains lethal in about 50% of patients despite comprehensive and intensive treatments.

      Read Full Article
    7. Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

      Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

      Mol Cancer Ther. 2018 Feb 28;:

      Authors: Sagnella SM, Trieu J, Brahmbhatt H, MacDiarmid JA, MacMillan A, Whan RM, Fife CM, McCarroll JA, Gifford AJM, Ziegler DS, Kavallaris M

      Read Full Article
      Mentions: Treatment
    8. A molecular map of childhood cancers

      A molecular map of childhood cancers

      Researchers led by Professor Stefan Pfister from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have been able to draw an extremely detailed molecular map of childhood cancers. In close collaboration with the German Cancer Consortium (DKTK) and the Society for Pediatric Oncology and Hematology (GPOH), they screened almost 1,000 tumor samples from […]

      The post A molecular map of childhood cancers appeared first on Healthcanal.com.

      Read Full Article
      Mentions: GPOH Genetics
    9. Cancer evolution, mutations, and clonal selection in relapse neuroblastoma.

      Cancer evolution, mutations, and clonal selection in relapse neuroblastoma.

      Cell Tissue Res. 2018 Feb 24;:

      Authors: Schulte M, Köster J, Rahmann S, Schramm A

      Abstract The notion of cancer as a complex evolutionary system has been validated by in-depth molecular analyses of tumor progression over the last years.

      Read Full Article
      Mentions: Treatment Relapse
    10. Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma.

      Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma.

      J Control Release. 2018 Feb 23;:

      Authors: Sama S, Woith E, Walther W, Jerz G, Chen W, Hart S, Melzig MF, Weng A

      Abstract Neuroblastoma represents the third most common malign neoplasm occurring in children and the most common in newborn.

      Read Full Article
    11. Molecular mechanisms and therapeutic targets in neuroblastoma.

      Molecular mechanisms and therapeutic targets in neuroblastoma.

      Pharmacol Res. 2018 Feb 18;:

      Authors: Johnsen JI, Dyberg C, Fransson S, Wickström M

      Abstract Neuroblastoma is the most common extracranical tumor of childhood and the most deadly tumor of infancy. It is characterized by early age onset and high frequencies of metastatic disease but also the capacity to spontaneously regress.

      Read Full Article
    12. Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

      Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

      Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine.

      Read Full Article
    13. Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity.

      Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity.

      J Int Adv Otol. 2018 Feb 20;:

      Authors: Serinan E, Altun Z, Aktaş S, Çeçen E, Olgun N

      Abstract OBJECTIVE: Cisplatin (CDDP) is an anti-neoplastic agent that has been used in treatments of both pediatric and adult cancers. It has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity. Lipoplatin (LIPO) is a nanomolecule with 110 nm diameter and composed of lipids and CDDP.

      Read Full Article
      Mentions: Side Effects
    14. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    15. Estrogen causes neuroblastoma cells to mature into neurons

      The female sex hormone estrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The studygives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment
    16. Oestrogen causes neuroblastoma cells to mature into neurons

      Oestrogen causes neuroblastoma cells to mature into neurons

      ( Karolinska Institutet ) The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that oestrogen treatment and overexpression of the oestrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The study, which is published in PNAS, gives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment MYCN
    17. Fertility preservation options in pediatric and adolescent patients with cancer.

      Fertility preservation options in pediatric and adolescent patients with cancer.

      Cancer. 2018 Jan 25;:

      Authors: Burns KC, Hoefgen H, Strine A, Dasgupta R

      Abstract The incidence of childhood cancer has steadily increased since the 1950s, with approximately 16,000 children diagnosed each year. However, with the advent of more effective multimodal therapies, childhood cancer survival rates have continued to improve over the past 40 years, with >80% of patients now surviving into adulthood.

      Read Full Article
    18. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    19. Microbiome predicts blood infections in pediatric cancer patients

      Microbiome predicts blood infections in pediatric cancer patients

      Cancer patients receive essential medicines, fluids, blood and nutrients through long, flexible tubes called central venous catheters, or central lines. But every year in the United States, these central lines are associated with an estimated 400,000 blood infections, many of which are fatal, and which cost the healthcare system upwards of $18 billion dollars annually. But what if some or even many of these infections aren't, in fact, introduced by central lines?

      Read Full Article
    1-24 of 244 1 2 3 4 ... 9 10 11 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles